Ixazomib

Form: Capsules

Strength: 2.3 mg, 3 mg, 4 mg

Reference Brands: Ninlaro® (EU & US)

Category: Oncology Cancer Care

Ixazomib Capsules, marketed under the brand name Ninlaro®, are a novel oral proteasome inhibitor used in combination therapies for multiple myeloma in patients who have received at least one prior treatment. Ixazomib works by blocking the 20S proteasome, disrupting protein homeostasis in cancer cells and promoting apoptosis. Available in 2.3 mg, 3 mg, and 4 mg capsule strengths, it provides a convenient oral option for patients and physicians. Manufactured under GMP-compliant facilities, Ixazomib is approved in both the US and EU markets, making it an attractive and effective B2B oncology solution for global pharmaceutical supply chains.